Long-term effects of spironolactone in peritoneal dialysis patients

Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Hirofumi Tamai, Takeyuki Hiramatsu, Hiroshige Ohashi, Isao Ito, Hirotake Kasuga, Masanobu Horie, Shoichi Maruyama, Yukio Yuzawa, Tatsuaki Matsubara, Seiichi Matsuo, M. Watanabe, H. Nishimura, M. Mizutani, H. Kinashi, A. Dambara, Y. Saka, S. Toda & 9 others S. Kimu, K. Minoshima, M. Yamaha, R. Takahashi, K. Kimura, T. Naruse, T. Matsuoka, Daijo Inaguma, K. Kurata

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

Original languageEnglish
Pages (from-to)1094-1102
Number of pages9
JournalJournal of the American Society of Nephrology
Volume25
Issue number5
DOIs
Publication statusPublished - 01-05-2014

Fingerprint

Spironolactone
Peritoneal Dialysis
Stroke Volume
Dialysis
Mineralocorticoid Receptor Antagonists
Angiotensin II Type 1 Receptor Blockers
Kidney
Control Groups
Hyperkalemia
Dialysis Solutions
Cardiomegaly
Left Ventricular Hypertrophy
Angiotensin-Converting Enzyme Inhibitors
Chronic Kidney Failure
Echocardiography
Creatinine
Heart Failure
Observation
Survival

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Ito, Y., Mizuno, M., Suzuki, Y., Tamai, H., Hiramatsu, T., Ohashi, H., ... Kurata, K. (2014). Long-term effects of spironolactone in peritoneal dialysis patients. Journal of the American Society of Nephrology, 25(5), 1094-1102. https://doi.org/10.1681/ASN.2013030273
Ito, Yasuhiko ; Mizuno, Masashi ; Suzuki, Yasuhiro ; Tamai, Hirofumi ; Hiramatsu, Takeyuki ; Ohashi, Hiroshige ; Ito, Isao ; Kasuga, Hirotake ; Horie, Masanobu ; Maruyama, Shoichi ; Yuzawa, Yukio ; Matsubara, Tatsuaki ; Matsuo, Seiichi ; Watanabe, M. ; Nishimura, H. ; Mizutani, M. ; Kinashi, H. ; Dambara, A. ; Saka, Y. ; Toda, S. ; Kimu, S. ; Minoshima, K. ; Yamaha, M. ; Takahashi, R. ; Kimura, K. ; Naruse, T. ; Matsuoka, T. ; Inaguma, Daijo ; Kurata, K. / Long-term effects of spironolactone in peritoneal dialysis patients. In: Journal of the American Society of Nephrology. 2014 ; Vol. 25, No. 5. pp. 1094-1102.
@article{4aa06cfb70c646b0b9968b92041ec48d,
title = "Long-term effects of spironolactone in peritoneal dialysis patients",
abstract = "ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.",
author = "Yasuhiko Ito and Masashi Mizuno and Yasuhiro Suzuki and Hirofumi Tamai and Takeyuki Hiramatsu and Hiroshige Ohashi and Isao Ito and Hirotake Kasuga and Masanobu Horie and Shoichi Maruyama and Yukio Yuzawa and Tatsuaki Matsubara and Seiichi Matsuo and M. Watanabe and H. Nishimura and M. Mizutani and H. Kinashi and A. Dambara and Y. Saka and S. Toda and S. Kimu and K. Minoshima and M. Yamaha and R. Takahashi and K. Kimura and T. Naruse and T. Matsuoka and Daijo Inaguma and K. Kurata",
year = "2014",
month = "5",
day = "1",
doi = "10.1681/ASN.2013030273",
language = "English",
volume = "25",
pages = "1094--1102",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

Ito, Y, Mizuno, M, Suzuki, Y, Tamai, H, Hiramatsu, T, Ohashi, H, Ito, I, Kasuga, H, Horie, M, Maruyama, S, Yuzawa, Y, Matsubara, T, Matsuo, S, Watanabe, M, Nishimura, H, Mizutani, M, Kinashi, H, Dambara, A, Saka, Y, Toda, S, Kimu, S, Minoshima, K, Yamaha, M, Takahashi, R, Kimura, K, Naruse, T, Matsuoka, T, Inaguma, D & Kurata, K 2014, 'Long-term effects of spironolactone in peritoneal dialysis patients', Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1094-1102. https://doi.org/10.1681/ASN.2013030273

Long-term effects of spironolactone in peritoneal dialysis patients. / Ito, Yasuhiko; Mizuno, Masashi; Suzuki, Yasuhiro; Tamai, Hirofumi; Hiramatsu, Takeyuki; Ohashi, Hiroshige; Ito, Isao; Kasuga, Hirotake; Horie, Masanobu; Maruyama, Shoichi; Yuzawa, Yukio; Matsubara, Tatsuaki; Matsuo, Seiichi; Watanabe, M.; Nishimura, H.; Mizutani, M.; Kinashi, H.; Dambara, A.; Saka, Y.; Toda, S.; Kimu, S.; Minoshima, K.; Yamaha, M.; Takahashi, R.; Kimura, K.; Naruse, T.; Matsuoka, T.; Inaguma, Daijo; Kurata, K.

In: Journal of the American Society of Nephrology, Vol. 25, No. 5, 01.05.2014, p. 1094-1102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term effects of spironolactone in peritoneal dialysis patients

AU - Ito, Yasuhiko

AU - Mizuno, Masashi

AU - Suzuki, Yasuhiro

AU - Tamai, Hirofumi

AU - Hiramatsu, Takeyuki

AU - Ohashi, Hiroshige

AU - Ito, Isao

AU - Kasuga, Hirotake

AU - Horie, Masanobu

AU - Maruyama, Shoichi

AU - Yuzawa, Yukio

AU - Matsubara, Tatsuaki

AU - Matsuo, Seiichi

AU - Watanabe, M.

AU - Nishimura, H.

AU - Mizutani, M.

AU - Kinashi, H.

AU - Dambara, A.

AU - Saka, Y.

AU - Toda, S.

AU - Kimu, S.

AU - Minoshima, K.

AU - Yamaha, M.

AU - Takahashi, R.

AU - Kimura, K.

AU - Naruse, T.

AU - Matsuoka, T.

AU - Inaguma, Daijo

AU - Kurata, K.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

AB - ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

UR - http://www.scopus.com/inward/record.url?scp=84906557574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906557574&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013030273

DO - 10.1681/ASN.2013030273

M3 - Article

VL - 25

SP - 1094

EP - 1102

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -